Drug Profile
Research programme: dual-variable domain immunoglobulins - AbbVie
Alternative Names: Dual-variable domain Ig; DVD-Ig™Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Immunoglobulins; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Interleukin 1 alpha inhibitors; Interleukin 1 beta inhibitors; Interleukin-17 inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)